Orient Pharma Co., Ltd. (TPEX:4166)
Taiwan
· Delayed Price · Currency is TWD 26.50
+0.15 (0.57%)
Apr 29, 2026, 1:30 PM CST
Orient Pharma Balance Sheet
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Cash & Equivalents | 587.6 | 84.5 | 83.32 | 76.43 | 130.92 | Upgrade
|
| Short-Term Investments | 39.8 | 24.8 | 29.8 | 20.8 | 20.8 | Upgrade
|
| Cash & Short-Term Investments | 627.4 | 109.3 | 113.12 | 97.23 | 151.72 | Upgrade
|
| Cash Growth | 474.04% | -3.38% | 16.34% | -35.92% | -20.30% | Upgrade
|
| Accounts Receivable | 248.52 | 278.18 | 179.31 | 69.39 | 63.09 | Upgrade
|
| Other Receivables | 16.38 | 10.36 | 8.16 | 12.91 | 16.82 | Upgrade
|
| Receivables | 264.89 | 288.54 | 187.47 | 82.3 | 79.9 | Upgrade
|
| Inventory | 322.39 | 279.56 | 233.97 | 194.18 | 156.88 | Upgrade
|
| Prepaid Expenses | 26.46 | 44.12 | 58 | 39.18 | 30.91 | Upgrade
|
| Other Current Assets | 18 | 6.91 | 29.7 | 10.24 | 19.89 | Upgrade
|
| Total Current Assets | 1,259 | 728.43 | 622.25 | 423.12 | 439.31 | Upgrade
|
| Property, Plant & Equipment | 835.58 | 891.83 | 944.96 | 903.28 | 769.71 | Upgrade
|
| Long-Term Investments | 12.83 | 13.65 | 1.88 | 3.05 | 1.75 | Upgrade
|
| Other Intangible Assets | 414.87 | 471.83 | 532.66 | 11.9 | 13.75 | Upgrade
|
| Long-Term Deferred Tax Assets | 362.29 | 397.98 | 451.46 | 452.04 | 439.2 | Upgrade
|
| Other Long-Term Assets | 53.65 | 16.87 | 9.47 | 54.18 | 100.1 | Upgrade
|
| Total Assets | 2,938 | 2,521 | 2,563 | 1,848 | 1,764 | Upgrade
|
| Accounts Payable | 62.07 | 36.14 | 55.57 | 61.97 | 19.6 | Upgrade
|
| Accrued Expenses | 83.89 | 69.82 | 62.04 | 53.5 | 59.07 | Upgrade
|
| Short-Term Debt | - | 250 | 314.5 | 68.5 | 161.5 | Upgrade
|
| Current Portion of Long-Term Debt | - | 40 | 60.71 | 24.08 | 23.83 | Upgrade
|
| Current Portion of Leases | 16.14 | 18.44 | 17.95 | 14.92 | 8.22 | Upgrade
|
| Current Unearned Revenue | 4.47 | 64.51 | 22.01 | 64.87 | 78.07 | Upgrade
|
| Other Current Liabilities | 20.54 | 8.35 | 30.56 | 63.22 | 69.17 | Upgrade
|
| Total Current Liabilities | 187.1 | 487.25 | 563.35 | 351.06 | 419.46 | Upgrade
|
| Long-Term Debt | - | 42.1 | 112.06 | 178.79 | 111.8 | Upgrade
|
| Long-Term Leases | 179.81 | 195.95 | 211.67 | 221.86 | 109.67 | Upgrade
|
| Pension & Post-Retirement Benefits | 6.81 | 5.86 | 5.09 | 5.94 | 6.85 | Upgrade
|
| Long-Term Deferred Tax Liabilities | 1.15 | 1.84 | - | - | 0.13 | Upgrade
|
| Total Liabilities | 374.88 | 733 | 892.18 | 757.65 | 647.9 | Upgrade
|
| Common Stock | 2,430 | 2,230 | 2,230 | 1,870 | 1,870 | Upgrade
|
| Additional Paid-In Capital | 369.05 | 1,130 | 1,130 | 932.15 | 932.15 | Upgrade
|
| Retained Earnings | -241.01 | -1,579 | -1,686 | -1,709 | -1,682 | Upgrade
|
| Comprehensive Income & Other | 5.08 | 6.05 | -3.83 | -2.89 | -4.6 | Upgrade
|
| Shareholders' Equity | 2,563 | 1,788 | 1,670 | 1,090 | 1,116 | Upgrade
|
| Total Liabilities & Equity | 2,938 | 2,521 | 2,563 | 1,848 | 1,764 | Upgrade
|
| Total Debt | 195.95 | 546.49 | 716.9 | 508.15 | 415.01 | Upgrade
|
| Net Cash (Debt) | 431.45 | -437.19 | -603.78 | -410.92 | -263.29 | Upgrade
|
| Net Cash Per Share | 1.87 | -1.96 | -2.71 | -2.20 | -1.41 | Upgrade
|
| Filing Date Shares Outstanding | 223.04 | 223.04 | 223.04 | 187 | 187 | Upgrade
|
| Total Common Shares Outstanding | 223.04 | 223.04 | 223.04 | 187 | 187 | Upgrade
|
| Working Capital | 1,072 | 241.18 | 58.9 | 72.07 | 19.86 | Upgrade
|
| Book Value Per Share | 11.49 | 8.01 | 7.49 | 5.83 | 5.97 | Upgrade
|
| Tangible Book Value | 2,149 | 1,316 | 1,138 | 1,078 | 1,102 | Upgrade
|
| Tangible Book Value Per Share | 9.63 | 5.90 | 5.10 | 5.76 | 5.89 | Upgrade
|
| Buildings | 796.79 | 794.16 | 786.78 | 744.9 | 682.91 | Upgrade
|
| Machinery | 454.15 | 439.37 | 430.96 | 367.95 | 361.11 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.